Come join us at the at the Oncofetal Ecosystem lab in vibrant Sydney. Reach out if you are interested in clinical research employing the leading single cell and spatial technologies in liver cancer
Read this @GenomeWeb article where I share our experience with working on @PixelgenTech ‘s single cell spatial proteomics to address ‘why some patients do not respond to immunotherapy’. #livercancer#immunotherapy
Very excited to co-lead @NHMRC 2023 Clinical Trial & Cohort Grant (6M AUD) with Jacob George for the clinical trial (DEFINERx050) and cohort (PRECISION). We will establish a pan-national HCC cohort across 5 states & 13 clinical sites to evaluate #oncofetal score and other biomarkers of IO response in #LiverCancer
Congratulations to all successful candidates! Specially @JenCurrenti who joined @SharmaaLab 2 years ago and have made significant contributions in understanding role of T-cells in HCC immunotherapy @CureCancerAu
🎇NEW YEAR, NEW PAPERS – “Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy” by @FGinhoux@asharmaiisc & Co.
Check it out👇
https://t.co/IGFDRcRhNV
https://t.co/S0mQTPCqvO
🔬💡 New insights from our @NatureCancer paper! We've uncovered a causal link between #oncfetal cells and post-surgery relapse in cancer patients. Our findings pave the way for adjunct immunotherapy treatments, offering hope to those at high risk.
https://t.co/M9go4mxKGd
So happy to have received the best oral presentation award at the LCC ASCM meeting 2023 🤩 thank you to my supervisor @asharmaiisc and my lab @SharmaaLab for their support !!